This is the article @NatureNV:
A tumour-cell lipid reprograms immune cells
doi.org/10.1038/d41586-024-0…
1
5
318
We were priviliged to write a News & Views article on the fantaststic work by the group of Anja Obenauf that was published online in Nature Nov 27th (Elewaut et al. doi.org/10.1038/s41586-024-0…).
You can read it online with this SharedIt link: rdcu.be/d3cRz
Thomas Tueting retweeted
Thanks for the shoutout!
Cancer cells blunt monocyte IFN while increasing PGE2 to inhibit T cell immunity @Nature @obenaufa @AnaisElewaut @guillemxtivill
nature.com/articles/s41586-0…
Thomas Tueting retweeted
I feel very honored that the lab’s work has been awarded with the Georges-Köhler-Prize 🏆 from the German Society of Immunology @dgfi_org! Teamwork is essential to our work. Thanks to the whole team, its talented current and past members, & our fantastic collaboration partners!
This Post is from an account that no longer exists. Learn more
Thomas Tueting retweeted
Congratulations Matteo and co. for this beautiful study!
💥 Exciting News! Our latest research is now online @NatImmunol! Discover how prior infection or vaccination provides antibody-independent protection against heterologous SARS-CoV-2 challenge! 🧵🔬 (1/10)
nature.com/articles/s41590-0…
2/ 🛡️ Shifting paradigms, our research highlights T cells' paramount role in defending against COVID-19 beyond antibody responses. Even in the complete absence of antibodies, T cells stand guard.
3/ 🧬 Our study utilized advanced mouse models, including a pioneering human/mouse ACE2 hybrid, to unveil that T cell immunity effectively counters various SARS-CoV-2 strains without relying on antibodies.
4/ 💪 Highlight of our findings: CD8+ T cells are crucial for combating severe infections, complemented by CD4+ T cells in less severe cases. The linchpin? Interferon-gamma (IFN-γ), driving this antibody-independent protection.
5/ 🔄 Demonstrated across models mimicking the spectrum of disease severity, this research shows that T cells not only prevent disease but also curb early SARS-CoV-2 replication.
6/ 📚 Building on the collective efforts of many in the field, our study underscores T cells' essential and sufficient role in safeguarding against SARS-CoV-2, reinforcing the critical importance of cellular immunity in the fight against COVID-19.
7/ 🌐 While our findings support vaccine strategies enhancing T cell responses, it's essential to acknowledge the efficacy of current vaccines in eliciting T cell immunity. We advocate for evaluating T cell responses alongside antibodies to fully assess vaccine effectiveness and explore targeted strategies for optimal T cell activation.
8/ 🙌 A heartfelt thank you to our incredible team and collaborators, especially lead author @ValeFuma91, along with key contributors Micol Ravà and Davide Marotta, as well as our collaborators Luca Guidotti, Marco Bianchi, and Raffaele De Francesco.
9/ 🌟Appreciation to our supporters @ERC, @AIRC_it, @EMBO_YIP, @ArmeniseHarvard, @mur_gov_, @SanRaffaeleMI, @MyUniSR, Fondazione SAME, Fondazione Prossimo Mio. Thanks also to our reviewers and Nick Bernard for their invaluable contributions to our journey.
10/ Dive deeper into our study to grasp its impact on immunology and future vaccine development. We're eager to hear your thoughts and engage in discussions! nature.com/articles/s41590-0…. Your feedback and insights are invaluable. 📖💭
Thomas Tueting retweeted
Very excited to share new work from the lab dissecting mechanisms of liver-metastatic organotropism in melanoma and other cancers. Huge congrats to fearless post-doc @meri_rogava (on the job market!) who led this multi-year study! Below a brief summary...
nature.com/articles/s43018-0…
Thomas Tueting retweeted
Online Now: Interferon-stimulated neutrophils as a predictor of immunotherapy response dlvr.it/T10XST
Thomas Tueting retweeted
We celebrate the 20th anniversary of our lab with a paper just out in the 50th anniversary special issue of @CellCellPress A great way to start 2024!
A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma: Cell cell.com/cell/fulltext/S0092…
Thomas Tueting retweeted
Proud to share our collaboration in the latest @CellCellPress paper led by @li_hanjie. The study presents an immune cell atlas & the dynamics of human macrophage specification in prenatal development. doi.org/10.1016/j.cell.2023.… (1/11)
Thomas Tueting retweeted
📢 Research Alert! 🧬🔬 🩺 We are super excited that our latest study, led by the great @RubenBill5 & Asa Wirapati, is out: science.org/doi/full/10.1126…
We set out to shed some light on the tumor microenvironment and its impact on cancer progression.
🧵
Thomas Tueting retweeted
1/ We're thrilled to share our preprint on Deep3P - a new approach that takes us on a deep dive into the world of brain tumors, using three-photon microscopy and #AI. This exciting endeavor is brought to life together with the amazing @Prevedel_Lab ! tinyurl.com/mpz3extr
Thomas Tueting retweeted
Thanks @Cancer_Cell for sharing, and grateful to reviewers and @Montse_Rojo_PhD for a constructive, engaging and fair review/revision process. Hard work by @triciahoho @JCA_Melms @meri_rogava with a product we are proud of.
Online Now: The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity dlvr.it/SqyWXh
Thomas Tueting retweeted
Ein interdisziplinäres Forscherteam der @unimedmagdeburg entdeckt neuen Mechanismus der #Krebsimmunabwehr und liefert damit einen wichtigen Beitrag zur Verbesserung von #Krebs-#Immuntherapien.
#TeamUMMD @Nature
Mehr erfahren med.uni-magdeburg.de/News/Ma…

ALT Ein interdisziplinäres Forschungsteam um die Autoren (v.l.) Bastian Kruse, Prof. Dr. Andreas Müller, Prof. Dr. Thomas Tüting und Dr. Anthony Buzzai von der Universitätsmedizin Magdeburg gewinnt neue Erkenntnisse, wie entzündliche Botenstoffe der Infektabwehr Krebszellen aus der Ferne in den Tod treiben können – ein wichtiger Beitrag zur Verbesserung von Krebs-Immuntherapien.
Thomas Tueting retweeted
My first first-author pub is finally out in @Cancer_Cell! Endless thanks to @BizarMd @JCA_Melms and @meri_rogava for all their guidance scientifically and personally that made this happen. Tweetorial below from our pre-print for now! authors.elsevier.com/c/1hFn3…
Very excited to share new work from the lab dissecting mechanisms of cancer immune evasion. True team effort led by MD/PhD student @triciahoho and post-docs @JCA_Melms @meri_rogava 1/14
biorxiv.org/content/10.1101/…
Thomas Tueting retweeted
Australia - 1st authority in world to approve & fund #neoadjuvant pembrolizumab in resectable stage IIIB-D #melanoma. So proud of my co-med director @ProfRScolyerMIA - submitted with me on behalf @MelanomaAus. Neoadjuvant clinical trials critical for zero deaths from #melanoma.
Thomas Tueting retweeted
A special thanks to our great collaborators including @OBechter and funders including the VIB grand challenge program @VIBLifeSciences @vib_ccb @Onco_KULeuven @FWOVlaanderen @Stkstichting @MelanomaReAlli
Thomas Tueting retweeted
(Even a small amount of) CD4 T-cells can unleash a robust anti-tumour response through a rather unexpected mechanism…for more about this read this important paper from the Tüeting lab. Happy we could contribute to a small piece…
Read our latest work on the power of CD4 T cells in cancer immunity:
nature.com/articles/s41586-0…
Read our latest work on the power of CD4 T cells in cancer immunity:
nature.com/articles/s41586-0…
Thomas Tueting retweeted
A question that has long obsessed us: are the "seeds" of metastasis built into the primary tumor? In our new paper ,@shruthy_suresh tackled this question by combining human transcriptomics with the #Zebrafish TEAZ method to come up with the answer: doi.org/10.1158/2159-8290.CD…
Thomas Tueting retweeted
We are now utilizing our technologies to develop mRNA and LNP-based treatments effective at the cell level. So if you're interested in doing transformative biomedical research for patients' lives, check out our new position and pass it along.
jobs.helmholtz-muenchen.de/j…






















